Jupiter Topco LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,348,843 shares of the biopharmaceutical company's stock, valued at approximately $105,570,000. Jupiter Topco LLC owned 1.19% of Halozyme Therapeutics at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of HALO. Measured Wealth Private Client Group LLC boosted its holdings in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 124 shares during the period. Larson Financial Group LLC increased its stake in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 343 shares during the period. MidFirst Bank acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth about $28,000. Finally, Quantbot Technologies LP purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $30,000. Institutional investors and hedge funds own 97.79% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. Leerink Partners upgraded shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. Benchmark reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Morgan Stanley lowered their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a research note on Tuesday, May 12th. Finally, Weiss Ratings lowered Halozyme Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Friday, August 14th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $91.20.
View Our Latest Analysis on HALO
Insider Buying and Selling at Halozyme Therapeutics
In other news, Director Bernadette Connaughton sold 1,626 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares of the company's stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $79,987,320.40. This trade represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 64,103 shares of company stock worth $5,226,496 over the last ninety days. Corporate insiders own 2.50% of the company's stock.
Halozyme Therapeutics Trading Down 2.1%
Shares of NASDAQ:HALO opened at $107.06 on Thursday. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $109.66. The company's 50 day moving average is $85.50 and its two-hundred day moving average is $74.39. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The company has a market cap of $12.15 billion, a PE ratio of 31.96, a P/E/G ratio of 0.44 and a beta of 0.85.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company's revenue was up 47.7% on a year-over-year basis. During the same period last year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.
About Halozyme Therapeutics
(
Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Halozyme Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.
While Halozyme Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
